Anurag S Rathore
Overview
Explore the profile of Anurag S Rathore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
253
Citations
1055
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hebbi V, Kumar J, Rathore A
Biotechnol Prog
. 2025 Feb;
:e70001.
PMID: 39964173
Pichia pastoris has been used as an expression system for multiple biotherapeutic products due to the unique advantages it offers with respect to cell density, protein titer, extracellular expression, and...
2.
Shrivastava A, Patil S, Shah R, Rathore A
BioDrugs
. 2025 Jan;
39(2):333-345.
PMID: 39873867
Background: With the expiration of patents for multiple biotherapeutics, biosimilars are gaining traction globally as cost-effective alternatives to the original products. Glycosylation, a critical quality attribute, makes glycosimilarity assessment pivotal...
3.
Ahmad A, Refaat H, Bhattacharya S, Gurvich V, Rathore A, Nejadnik R, et al.
Int J Pharm
. 2025 Jan;
671:125275.
PMID: 39870255
For monoclonal antibody drug products as for other biologics, while the innovator drug products first becomes commercially available, they are often followed by one or more biosimilar products. These biosimilars...
4.
Sreenivasan S, Rathore A
Pharm Res
. 2025 Jan;
42(2):335-351.
PMID: 39849217
Purpose: Therapeutic monoclonal antibodies (mAbs) are prone to degradation via aggregation and fragmentation. In this study, forced degradation of trastuzumab (TmAb) was explored in saline and in-vitro models having HO...
5.
Gangwar N, Dixit N, Rathore A
Appl Microbiol Biotechnol
. 2025 Jan;
109(1):16.
PMID: 39841264
Monoclonal antibodies are extensively used as biotherapeutics for treatment of a variety of diseases. Glycosylation of therapeutic antibodies is considered a critical quality attribute as it influences the effector function,...
6.
Sarin D, Chakraborty D, Sreenivasan S, Mishra A, Rathore A
J Pharm Sci
. 2025 Jan;
114(2):1398-1409.
PMID: 39798696
Stability of complex biotherapeutics like monoclonal antibodies is paramount for their safe and efficacious use. Excipients are inactive ingredients that are added to the purified product so as to offer...
7.
Anupa A, Jesubalan N, Trivedi R, Nitika N, Buddhiraju V, Runkana V, et al.
J Chromatogr A
. 2025 Jan;
1742():465642.
PMID: 39778281
Recent advancements in technology, such as the emergence of artificial intelligence (AI) and machine learning (ML), have facilitated the progression of the biopharmaceutical industry toward the implementation of Industry 4.0....
8.
Refaat H, Ahmad A, Kamel E, Gurvich V, Rathore A, Suryanarayanan R, et al.
Int J Pharm
. 2025 Jan;
670:125146.
PMID: 39743160
Buffer exchange is a critical step in biologics development, playing a pivotal role in removing contaminants, adjusting sample conditions, and facilitating compatibility studies. The efficiency of centrifugal concentrators for polysorbate...
9.
Anupa A, Rathore A
Protein Expr Purif
. 2024 Dec;
227:106647.
PMID: 39701440
Antigen binding fragments (Fabs) are an emerging class of biotherapeutics, widely accepted as an alternative to the traditional monoclonal antibodies (mAbs). The small size of the Fabs offers better tissue...
10.
Patil S, Rajak R, Ramteke M, Rathore A
Comput Biol Med
. 2024 Dec;
185():109501.
PMID: 39626456
Unified translation of medical images from one-to-many distinct modalities is desirable in healthcare settings. A ubiquitous approach for bilateral medical scan translation is one-to-one mapping with GANs. However, its efficacy...